Immune thrombocytopenia (ITP) is treated in stages, starting with corticosteroids and escalating to more targeted therapies if platelets don’t respond or the condition becomes chronic. Not everyone with ITP needs treatment. The American Society of Hematology recommends observation alone for adults whose platelet count stays at or above 30,000/μL and who have no bleeding symptoms. Treatment typically begins when counts drop below 30,000/μL or when significant bleeding occurs.
ITP is defined as a platelet count below 100,000/μL with no other identifiable cause for the low count. It’s a diagnosis of exclusion, meaning your doctor rules out other reasons for low platelets before settling on ITP. Understanding the treatment ladder helps you know what to expect at each stage and why your doctor might recommend switching approaches.
Corticosteroids: The Starting Point
The first treatment for most people with ITP is a corticosteroid, either prednisone taken daily for two to four weeks with a gradual taper, or high-dose dexamethasone given for just four days. Both aim to suppress the immune system’s attack on your platelets.
Dexamethasone works faster. At two weeks, about 79% of patients see a platelet response compared to 59% with prednisone. But that early advantage fades. By six months, the two approaches perform similarly, with response rates of roughly 54% and 43% respectively. The choice often comes down to your doctor’s preference and how quickly your platelets need to rise. Dexamethasone’s short course can be appealing since it avoids weeks of steroid side effects like weight gain, mood changes, and trouble sleeping.
The key limitation of corticosteroids is that many people relapse once the medication is tapered. If your platelets drop again after stopping steroids, or if you need ongoing steroids to maintain a safe count, the next step is a second-line therapy.
When Platelets Drop Dangerously Low
If you’re actively bleeding or your platelet count falls to critically low levels, faster-acting treatments are used alongside or instead of steroids. Intravenous immunoglobulin (IVIg) is the most common emergency option. It floods your system with antibodies that temporarily block the immune destruction of platelets, and it raises counts faster than any other approach.
Anti-D immunoglobulin is another option for people who are Rh-positive and still have their spleen. It works by redirecting the immune system’s attention away from platelets. The peak platelet response after a standard dose typically occurs around 72 hours after infusion. A higher dose can speed that timeline. In head-to-head comparisons in children with acute ITP, IVIg raised platelets significantly faster than anti-D, which is why IVIg remains the go-to for true emergencies. Platelet transfusions may also be given during life-threatening bleeding, though their effect is short-lived since the same immune process destroys the transfused platelets.
TPO Receptor Agonists for Chronic ITP
If ITP persists beyond the initial months or relapses after steroids, medications that stimulate your body to produce more platelets become the mainstay of treatment. These are called thrombopoietin receptor agonists (TPO-RAs), and they work by mimicking the natural hormone that tells your bone marrow to make platelets. Three are widely available, each with a different profile.
Romiplostim is a weekly injection given under the skin, either at a clinic or self-administered at home. It requires regular dose adjustments based on platelet count monitoring.
Eltrombopag is a daily pill, but it comes with dietary restrictions. You need to avoid calcium-rich foods and certain supplements around the time you take it because they interfere with absorption. It also requires regular liver function monitoring and starts at a lower dose for people of East Asian ancestry or those with liver problems.
Avatrombopag is also a daily pill, starting at 20 mg. It has fewer restrictions than eltrombopag: no dietary limitations, no routine liver monitoring requirement, and no dose adjustment needed for liver impairment.
All three are effective. In network analyses comparing them to placebo, each showed dramatically higher odds of achieving a durable platelet response. Romiplostim and eltrombopag significantly reduced the need for rescue therapy. Avatrombopag stood out for bleeding reduction, cutting the incidence of any bleeding events by about 66% compared to placebo and performing significantly better than both eltrombopag and romiplostim on that measure. If one TPO-RA stops working or causes side effects, switching to another is a reasonable strategy. Over 75% of patients respond after switching, even those who became resistant to their first one.
Rituximab as an Alternative
Rituximab takes a different approach. Instead of boosting platelet production, it depletes the B cells responsible for making the antibodies that destroy your platelets. The standard regimen is a weekly intravenous infusion for four consecutive weeks.
The response is meaningful but not permanent for most people. About 40% of patients still respond at one year, dropping to 30% at two years. By five years, only 21% to 26% remain in remission. That decline means rituximab works best for people hoping to achieve a treatment-free period rather than a lifelong cure. It’s often considered when TPO-RAs aren’t suitable or when avoiding long-term daily medication is a priority.
Fostamatinib: A Different Mechanism
Fostamatinib is an oral medication that works by blocking a signaling enzyme inside immune cells. By interrupting this signal, it reduces the ability of immune cells to recognize and destroy antibody-coated platelets. The starting dose is taken twice daily, and if platelet counts haven’t reached 50,000/μL after four weeks, the dose can be increased.
The most common side effects are diarrhea (affecting about 28% of patients) and high blood pressure (15%). Blood pressure monitoring is important while on this medication. Fostamatinib fills a useful niche for people who haven’t responded to or can’t tolerate TPO-RAs and rituximab.
FcRn Inhibitors: A Newer Option
Efgartigimod represents one of the newest treatment classes for ITP. It works by blocking a receptor that normally recycles antibodies in your body, causing harmful antibodies (including the ones attacking your platelets) to be broken down faster than usual. This lowers total antibody levels and reduces platelet destruction.
In the phase III ADVANCE IV trial, about 22% of patients on efgartigimod achieved a sustained platelet response over a six-week assessment window, compared to 5% on placebo. Looking at broader response criteria, over half (52%) of treated patients achieved at least a partial response versus 20% on placebo. Patients on efgartigimod averaged about six weeks of platelet counts at or above 50,000/μL, compared to roughly one and a half weeks for those on placebo. This class of therapy is particularly relevant for people with chronic ITP who have cycled through other options.
Splenectomy: Still on the Table
Removing the spleen was once the standard second-line treatment for ITP. The spleen is both a major site where coated platelets are destroyed and a key location where the anti-platelet antibodies are produced. Splenectomy achieves a lasting remission in roughly two-thirds of patients, making it one of the most effective single interventions available. However, it’s now typically reserved for people who don’t respond to multiple medical therapies. The shift reflects both the availability of effective medications and the lifelong increased infection risk that comes with living without a spleen.
ITP During Pregnancy
Pregnancy adds specific considerations because many ITP medications aren’t safe for a developing baby. Corticosteroids and IVIg remain the primary options. The treatment targets shift to focus on delivery safety: a platelet count above 50,000/μL is considered safe for both vaginal and cesarean delivery, while epidural anesthesia requires a count of at least 80,000/μL. Many women with mild ITP can be monitored without treatment through most of pregnancy, with intervention timed to ensure safe counts as delivery approaches.
Choosing the Right Approach
ITP treatment is not one-size-fits-all. The choice between therapies depends on how low your platelets are, whether you’re bleeding, how long you’ve had ITP, your other health conditions, and what matters to you practically. Someone who travels frequently might prefer an oral TPO-RA over weekly injections. Someone hoping to avoid lifelong medication might try rituximab for a shot at sustained remission. A person with liver disease would need to steer away from eltrombopag.
The platelet count that triggers treatment also varies by person. A count of 25,000/μL in someone with no bleeding and a sedentary lifestyle may be managed differently than the same count in someone who takes blood thinners or has an active job with injury risk. Treatment decisions in ITP are about balancing bleeding risk against treatment side effects, and that balance looks different for every patient.